Iovance Biotherapeutics, Inc. Common Stock
$10.14
$0.27 (+2.68%)
$10.12Day Range$10.98
Key Statistics
Market Cap
$4.47B
Shares Outstanding
453.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 26, 2010
Round Lot
100
Locale
US
Trading Data
Day Open
$10.25
Day High
$10.98
Day Low
$10.12
Volume
17.02M
VWAP
$10.55
Prev Close
$9.87
Transactions
--
Acc. Volume
--
About Iovance Biotherapeutics, Inc. Common Stock
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836975 employees825 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070(650) 260-7120IPO May 26, 2010US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001425205
- Composite FIGI
- BBG000FTLBV7
- Share Class FIGI
- BBG001T2PM32
- Ticker Root
- IOVA
- SIC Code
- 2836
About Iovance Biotherapeutics, Inc. Common Stock (IOVA) Stock
Iovance Biotherapeutics, Inc. Common Stock (IOVA) closed the 2026-09-17 session at $10.13, up 2.68% versus the previous close (+0.27). The stock opened at $10.25 and traded between $10.12 and $10.98 during that session. Session trading volume was 17.0M shares. The volume-weighted average price (VWAP) is $10.55.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Iovance Biotherapeutics, Inc. Common Stock has a market capitalization of $4.47 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. IOVA is listed on the XNAS exchange. The company employs approximately 975 people. Iovance Biotherapeutics, Inc. Common Stock is headquartered in SAN CARLOS, CA. The recorded listing date is 2010-05-26.
On this page you can find market IOVA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.